Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A vial containing the Pfizer-Biontech COVID-19 vaccine at a coronavirus vaccination center on Jan. 8, 2021 in Magdeburg, eastern Germany.


Proud of their national reputation for efficiency, Germans are growing increasingly frustrated by the slow rollout of a COVID-19 vaccine its scientists helped develop.

Scarce vaccine supply, cumbersome paperwork, a lack of health care staff and an aged and immobile population are hampering efforts to get early doses of a vaccine made by U.S.-based Pfizer and German partner BioNTech into the arms of the people.

Germany has set up hundreds of vaccination centres in sports halls and concert arenas and has the infrastructure to administer up to 300,000 shots a day, Health Minister Jens Spahn said.

Story continues below advertisement

But the majority are standing empty, with most states not planning to open centres until mid-January as they prioritize sending mobile teams into care homes.

A day spent with a vaccination team in the small town of Dillenburg, 100 km (60 miles) to the north of Germany’s financial capital Frankfurt, shows just how painstaking the task is.

The team starts out by loading a cool-box containing 84 doses of the Pfizer vaccine defrosted overnight into a waiting ambulance, and setting out for the Elisabeth residential care home.

There they are met by manager Peter Bittermann, who has already dealt with the forms needed to vaccinate residents and staff, and provided space for the shots to be administered and recipients monitored post-vaccination.

The four-member immunization team, plus two trainees, has just a few hours to dispense the temperature-sensitive Pfizer vaccine before it is no longer fit for use.

The German Red Cross needs an extra 350 people to run its local vaccination campaign, said Nicole Fey, spokeswoman of the local district administration.

“We’ve been able to recruit some, but there can never be enough,” she told Reuters TV.

Story continues below advertisement


In the first two weeks of its vaccination drive Germany has given 533,000 shots, just two-fifths of the 1.3 million doses received. Britain, by contrast, has reached the 2 million mark.

Israel, the world leader in terms of the share of population covered, is inoculating 150,000 people daily, with its universal and digitally enabled health care system making it easier to schedule appointments.

Germany’s larger size and federal set-up are complicating operations, a problem also faced in the United States.

Elsewhere in Europe, the decentralization of Spain’s vaccination operation has exposed differences between regions and led to tensions with the central government.

Germany’s 16 states blame the federal government for not securing enough doses. Doctors in some centres say shifts have been cancelled. In Berlin, one vaccination centre was opened, only to be closed over New Year due to a lack of shots.

Spahn says manufacturing problems rather than too few orders are to blame for the limited supply, after Pfizer and BioNTech in December halved their production forecast to 50 million doses by year-end. Each recipient requires two shots.

Story continues below advertisement

The government is working with BioNTech to open a new production site in the western town of Marburg, he said. BioNTech’s chief executive said last week the Marburg plant may enter service in February, ahead of schedule.

“With the capacity we have already created in Germany, we will be able to carry out between 250,000 and 300,000 vaccinations per day – when we have the vaccine doses,” Spahn said this week.

Germany expects to receive 5.3 million shots from Pfizer/BioNTech by mid-February and another 2 million doses of a second vaccine from Moderna, just approved by the European Union, by the end of March.

Yet this will barely be enough to cover the 5.7 million people, or 6.8% of the population, aged over 80.


As in Spain, state-by-state performance in Germany varies widely. Top of the class is Mecklenburg-Vorpommern in the north, with 15.6 vaccinations per 1,000 residents, while Saxony has a rate of just 4.4.

In Thuringia, another laggard, state premier Bodo Ramelow said on Tuesday that many doses sent to hospitals had been returned. “If the brakes come on at a vaccination rate of 30 or 33%, we have a real problem,” he told Deutschlandfunk radio.

Story continues below advertisement

In Saxony, the social affairs ministry said missing consent forms, challenges with route planning, COVID-19 outbreaks in homes and last-minute cancellations had slowed its rollout.

Shots in Saxony were stored centrally until recently, meaning mobile teams had to drive long distances before heading to care homes.

In contrast to Dillenburg, Saxony has been overrun by people volunteering for its vaccination drive, said Lars Werthmann, regional logistics chief at the German Red Cross.

“The next mammoth task is to co-ordinate all these people,” Werthmann said.

Doctors meanwhile express frustration at appointment booking systems that vary from state to state, saying they cause confusion and erode trust.

To speed up the rollout of COVID-19 shots, Germany should distribute them through its network of family doctors’ practices as soon as there is a vaccine that can be easily stored in a fridge, said Berlin pediatrician Burkhard Ruppert.

Story continues below advertisement

Germany is hoping to administer shots at doctors’ practices in a second phase.

“Our strength in Germany is this outpatient care system,” said Ruppert, who heads a local doctors’ association. “We’re not a country of large-scale managed systems like the United Kingdom or Israel might be.”

“We are in a race against a virus,” he added. “We will only win if we vaccinate as much and as fast as possible.”

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies